Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22165595 | 0.98 | KEAP1 (0.47) | KEAP1ALDH1A1ALOX15KDM4ETDP1 | |
| SCHEMBL5990597 | 0.98 | KEAP1 (0.47) | KEAP1ALDH1A1ALOX15KDM4ETDP1 | |
| Trifluoroacetic Acid SCHEMBL20482045 | 0.91 | KEAP1 (0.41) | KEAP1ALDH1A1ALOX15KDM4ETDP1 | |
| Tromethamine SCHEMBL16115022 | 0.87 | KEAP1 (0.39) | KEAP1ALDH1A1KDM4ETDP1PARP1 | |
| SCHEMBL663849 | 0.84 | PARP1 (0.56) | ALDH1A1ALOX15KDM4EPARP1SMN1; SMN2 | |
| SCHEMBL1297899 | 0.84 | PARP1 (0.41) | KEAP1ALDH1A1ALOX15KDM4ETDP1 | |
| SCHEMBL2646903 | 0.84 | PARP1 (0.41) | ALDH1A1ALOX15KDM4ETDP1PARP1 | |
| Hydrochloric Acid SCHEMBL7358641 | 0.82 | PARP1 (0.54) | ALDH1A1ALOX15KDM4EPARP1SMN1; SMN2 | |
| Potassium Ion SCHEMBL1578580 | 0.82 | PARP1 (0.39) | KEAP1ALDH1A1ALOX15KDM4ETDP1 | |
| SCHEMBL30448349 | 0.82 | ALDH1A1 (0.42) | KEAP1ALDH1A1ALOX15KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090530-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | TERNS PHARMACEUTICALS, INC. | 2025-03-20 | — | — | US | claimed |
| WO-2025049931-A1 | COMBINATIONS COMPRISING BCR:ABL-1 INHIBITOR AND A SECOND TYROSINE KINASE INHIBITOR FOR USE IN THE TREATMENT OF CANCER | TERNS PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| CN-117696012-A | Metal organic framework material and preparation method and application thereof | 浙江大学 | 2024-03-15 | — | — | CN | claimed |
| EP-3852745-A2 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. (US) | 2021-07-28 | — | — | EP | claimed |
| CN-112592485-A | Preparation of polyion liquid functionalized MOFs material and application of polyion liquid functionalized MOFs material in synthesis of isopulegol | 福州大学 | 2021-04-02 | — | — | CN | claimed |
| US-10604493-B2 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-03-31 | — | — | US | claimed |
| WO-2020061086-A2 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. (US) | 2020-03-26 | — | — | WO | claimed |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. (US) | 2020-03-19 | — | — | US | claimed |
| CN-106032378-B | New A RB compound and application thereof | 武汉启瑞药业有限公司 | 2019-10-25 | — | — | CN | claimed |
| CN-109771650-A | The composition being made of rush histamine release object and two substituted biphenyl derivatives | 黄泳华 | 2019-05-21 | — | — | CN | claimed |
| US-5753651-A | Use of AT1 antagonist such as irbesartan or candesartan cilexetil, among others; premenstrual syndrome (PMS) | DEPADOVA ANTHONY S (US) | 1998-05-19 | — | — | US | claimed |
| EP-0546358-B1 | Pharmaceutical compositions with angiotensin-II-antagonistic activity | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-08-27 | — | — | EP | claimed |
| EP-0759754-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DePadova, Anthony S. (US) | 1997-03-05 | — | — | EP | claimed |
| US-5534534-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-09 | — | — | US | claimed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | claimed |
| EP-0612524-A1 | Angiotensin II antagonists for the treatment of viral diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | claimed |
| CN-1086998-A | Combination of oral medication and preparation method | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-05-25 | — | — | CN | claimed |
| EP-0546358-A2 | Pharmaceutical compositions with angiotensin-II-antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-16 | — | — | EP | claimed |
| CN-1072338-A | Combination of oral medication and preparation method | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-05-26 | — | — | CN | claimed |
| US-4662905-A | REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE | Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) | 1987-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090530-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | ABL2, ABL1, BCR | KEAP1 1440/4885ALDH1A1 1452/4885ALOX15 3837/4885 |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | KEAP1 720/4885ALDH1A1 1027/4885ALOX15 3188/4885 |
| US-10604493-B2 | Compositions, methods of use, and methods of treatment | LIPA, LCT, GAA | KEAP1 2454/4885ALDH1A1 780/4885ALOX15 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.